THERIVA BIOLOGICS, INC. (TOVX)

Every figure this model derived for TOVX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 35,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 14,202,961 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 13,671,000 AssetsCurrent 2026-06-30
current liabilities 12,111,000 LiabilitiesCurrent 2026-06-30
equity 12,187,000 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 2026-06-30
interest expense 61,000 InterestExpenseDebt 2025-12-31
ocf -12,742,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 300,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 651,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TOVX on one particular measure came for.

RatioValue
current ratio1.13
current ratio reported1.13
dilution pct801.92
interest cover-195.49
sbc pct revenue217.0

What to be careful about

What this model itself distrusts about TOVX's figures. Written by the derivation as it ran, not added afterwards.